Recombinant activated factor VII;Factor VII activado recombinante

Medicina Intensiva

Volumn 31, Issue 6, 2007, Pages 326-330

  Quintana Diaz M ^a   Sanchez Casado M ^a   Mateos, A García De Lorenzo ^b  

^a HOSPITAL NUESTRA SEÑORA DEL PRADO   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Factor VII; Massive bleeding; Recombinant activated factor VII

Indexed keywords

BLOOD CLOTTING FACTOR 7; RECOMBINANT BLOOD CLOTTING FACTOR 7; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ARTERY THROMBOSIS; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; DISEASE SEVERITY; DRUG INDICATION; HEMOPHILIA; HEMOSTASIS; HUMAN; PROTEIN EXPRESSION; PROTHROMBIN TIME; REVIEW; STROKE; THROMBUS; VEIN THROMBOSIS;

EID: 34547697426     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/S0210-5691(07)74831-3     Document Type: Article

References (27)

1. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: Current practices and unresolved questions. Stroke. 2006;37:256-62.
2. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542-7.
3. Ghorashian S, Hunt BJ. "Off-license" use of recombinant activated factor VII. Blood Rev. 2004;18:245-59.
4. Mayer SA, Brun NC, Bergtrup K, Broderick J, Davis S, Diringer MN, et al, for the Recombinat Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-85.
5. Rhodes JD, Filoromo CH, Murray A, Lemons NV, Badr A, Gómez CR. Impact of treatment of intracerebral hemorrhage with recombinant factor VII. Stroke. 2006;37:723.
6. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerlev J, et al. Recombinant activated factor VII for adjuntive hemorrhage control in trauma. J Trauma. 2001;51:431-8.
7. Sauaia A, Moore FA, Moore EE, Moser KS, Brennan R, Read RA, et al. Epidemiology of trauma deaths; a reassessment. J Trauma. 1995;38:185-93.
8. Dutton RP, McCunn M, Hyder M, D'Angelo M, O'Connor J, Hess JR, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma. 2004;57:709-19.
9. Boffard KD, Riou B, Warren B, Chomg PIT, Rizoli S, Rossaint R, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trial. J Trauma. 2005;59:8-18.
10. Martinowitz U, Michaelson M; The Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost. 2005;3:640-8.
11. Schreiber MA. Coagulopathy in the trauma patient. Curr Opin Crit Care. 2005;11:590-7.
12. Friederich PW, Henny CP, Messenlink E, Geerdink MG, Keller T, Kurth KH, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet. 2003;361:201-5.
13. Karadimov D, Krassimir B, Nachkov Y, Platikanov V. Use of activated recombinant factor VII (NovoSeven) during neurosurgery. J Neurosurg Anesthesiol. 2003;15:330-2.
14. Slappendel R, Huvers FC, Benraad B, Novakova I, van Hellemondt GG. Use of recombinant factor VIIa (NovoSeven) to reduce postoperative bleeding after total hip arthroplasty in a patient with cirrhosis and thrombocytopenia. Anesthesiology. 2002;96:1525-7.
15. Al Douri M, Shafi T, Al Khudairi D, Al Bokhari E, Black L, Akinwale N, et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis. 2000;11 Suppl 1:S121-7.
16. Naik VN, Mazer CD, Latter DA, Teitel JM, Hare GM. Successful treatment using recombinant factor VIIa for severe bleeding post cardiopulmonary bypass. Can J Anaesth. 2003;50:599-602.
17. Stratmann G, Russell IA, Merrick SH. Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair. Ann Thorac Surg. 200;76:2094-7.
18. Kastrup M, von Heymann C, Hotz H, Konertz WF, Ziemer S, Kox WJ et al. Recombinant factor VIIa after aortic valve replacement in a patient with osteogenesis imperfecta. Ann Thorac Surg. 2002;74:910-12.
19. Vlot AJ, Mackaay AJC, Kramer MHH, Gaillard CAJM. Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII. Am J Med. 2000;108:421-3.
20. Boehlen F, Morales MA, Fontana P, Ricou B, Irion O, de Moerloose P, et al. Prolonged treatment of massive postpartum haemorrhage with recombinant factor VIIa: Case report and review of the literature. Br J Obstet Gynaecol. 2004;111:284-7.
21. Bouwmeester FW, Jonkhoff AR, Verheijen RH, van Geijn HP. Successful treatment of life-threatening postpartum hemorrhage with recombinant activated factor VII. Obstet Gynecol. 2003;101:1174-6.
22. Bosch J, Thabut D, Bendtsen F, D'Amico G, Albillos A, González Abraldes J, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized double-blind trial. Gastroenterology. 2004;127:1123-30.
23. Jeffers K, Chalasani N, Balart L, Pyrsopoulos N, Erhardtsen E. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology. 2002;123:118-26.
24. Meijer K, Hendriks HG, De Wolf JT, Klompmaker IJ, Lisman T, Hagenaars AA, et al. Recombinant factor VIIa in orthotopic liver transplantation: Influence on parameters of coagulation and fibrinolysis. Blood Coagul Fibrinolysis. 2003;14:169-74.
25. Shami VM, Caldwell SH, Hespenheide EE, Arseneau KO, Bickston SJ, Macik BG. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl. 2003;9:138-43.
26. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293-8.
27. Product Information. 27/01/04. Novoseven EMEA-H-074-II-29.